Eqis Capital Management Inc. purchased a new stake in CryoLife, Inc. (NYSE:CRY) during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm purchased 17,317 shares of the medical equipment provider’s stock, valued at approximately $345,000. Eqis Capital Management Inc. owned 0.05% of CryoLife as of its most recent SEC filing.
Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Russell Investments Group Ltd. purchased a new position in CryoLife during the fourth quarter valued at approximately $882,000. Comerica Bank raised its position in CryoLife by 6.3% in the fourth quarter. Comerica Bank now owns 28,727 shares of the medical equipment provider’s stock valued at $550,000 after buying an additional 1,714 shares during the period. State Street Corp raised its position in CryoLife by 19.4% in the fourth quarter. State Street Corp now owns 694,877 shares of the medical equipment provider’s stock valued at $13,308,000 after buying an additional 112,966 shares during the period. Dimensional Fund Advisors LP raised its position in CryoLife by 8.1% in the fourth quarter. Dimensional Fund Advisors LP now owns 1,749,123 shares of the medical equipment provider’s stock valued at $33,496,000 after buying an additional 131,597 shares during the period. Finally, FMR LLC raised its position in CryoLife by 19.8% in the fourth quarter. FMR LLC now owns 479,081 shares of the medical equipment provider’s stock valued at $9,174,000 after buying an additional 79,081 shares during the period. 69.22% of the stock is currently owned by institutional investors.
CryoLife, Inc. (NYSE CRY) traded up 0.26% during trading on Friday, hitting $19.05. The stock had a trading volume of 88,610 shares. The stock has a market cap of $637.15 million, a PE ratio of 57.73 and a beta of 0.97. The firm’s 50-day moving average price is $19.18 and its 200-day moving average price is $17.98. CryoLife, Inc. has a 1-year low of $14.03 and a 1-year high of $20.30.
CryoLife (NYSE:CRY) last released its quarterly earnings data on Monday, July 24th. The medical equipment provider reported $0.12 earnings per share for the quarter, topping the consensus estimate of $0.10 by $0.02. The business had revenue of $47.80 million during the quarter, compared to analyst estimates of $47.02 million. CryoLife had a return on equity of 7.41% and a net margin of 6.16%. The company’s revenue was up 1.5% compared to the same quarter last year. During the same period last year, the company posted $0.13 EPS. On average, equities research analysts predict that CryoLife, Inc. will post $0.43 earnings per share for the current fiscal year.
TRADEMARK VIOLATION WARNING: “Eqis Capital Management Inc. Buys New Stake in CryoLife, Inc. (CRY)” was originally reported by Community Financial News and is the sole property of of Community Financial News. If you are viewing this piece on another domain, it was copied illegally and republished in violation of US and international trademark & copyright laws. The correct version of this piece can be read at https://www.com-unik.info/2017/08/19/eqis-capital-management-inc-buys-new-position-in-cryolife-inc-cry-updated-updated-updated.html.
CRY has been the topic of several analyst reports. Northland Securities reiterated a “buy” rating and issued a $23.50 target price on shares of CryoLife in a research note on Friday, April 28th. Zacks Investment Research upgraded CryoLife from a “hold” rating to a “buy” rating and set a $21.00 price target on the stock in a research note on Thursday, June 8th. Finally, BidaskClub downgraded CryoLife from a “buy” rating to a “hold” rating in a research note on Monday, July 24th. One analyst has rated the stock with a sell rating, one has assigned a hold rating and three have issued a buy rating to the company. The stock presently has a consensus rating of “Hold” and an average target price of $22.00.
In other news, VP Amy Horton sold 9,577 shares of the stock in a transaction on Tuesday, June 27th. The stock was sold at an average price of $20.00, for a total value of $191,540.00. Following the completion of the sale, the vice president now owns 112,282 shares in the company, valued at $2,245,640. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. 6.00% of the stock is owned by corporate insiders.
CryoLife Company Profile
CryoLife, Inc (CryoLife) is a medical device manufacturer and processor, and is engaged in the distribution of medical devices and implantable human tissues used in cardiac surgical procedures. The Company operates through two segments: Medical Devices and Preservation Services. The Medical Devices segment includes medical devices, such as BioGlue Surgical Adhesive, BioFoam Surgical Matrix, On-X Life Technologies Holdings, Inc valves and surgical products, CardioGenesis cardiac laser therapy product line, PerClot and PhotoFix.
What are top analysts saying about CryoLife Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for CryoLife Inc. and related companies.